Yes, it is safe to start antivirals without ultrasound or genotype results in patients without evidence of decompensated cirrhosis
In patients with chronic hepatitis C who have no clinical evidence of decompensated cirrhosis, you can safely initiate pangenotypic antiviral therapy without waiting for ultrasound results or genotype testing. This simplified treatment approach is explicitly endorsed by current guidelines to improve access to care and increase cure rates 1.
Key Requirements Before Starting Treatment
The only essential information needed to initiate therapy is:
- Proof of HCV viremia (HCV RNA or HCV core antigen positive)
- Assessment for decompensated cirrhosis (clinical evaluation for ascites, encephalopathy, variceal bleeding, or jaundice)
- Drug-drug interaction screening 1
Clinical Assessment for Cirrhosis Status
Without ultrasound, you can assess cirrhosis status through:
- Clinical examination for stigmata of chronic liver disease
- Laboratory markers: Calculate FIB-4 or APRI scores using routine labs (AST, ALT, platelets, age) 1
- Child-Pugh score if cirrhosis is suspected clinically
If you cannot determine cirrhosis status definitively, use a universal 12-week treatment duration regardless of the regimen chosen 1.
Recommended Pangenotypic Regimens (No Genotype Needed)
For patients without cirrhosis or with compensated (Child-Pugh A) cirrhosis:
- Sofosbuvir/velpatasvir for 12 weeks, OR
- Glecaprevir/pibrentasvir for 8 weeks (treatment-naïve without cirrhosis) or 12 weeks (treatment-experienced or compensated cirrhosis) 1
These regimens work across all HCV genotypes with SVR rates exceeding 95% in most populations 1.
Important Caveats
Do NOT start treatment if:
- Clinical signs of decompensation are present (ascites, encephalopathy, variceal bleeding, jaundice) - these patients require genotype testing and specialized regimens with ribavirin 2
- Child-Pugh B or C cirrhosis is suspected - protease inhibitors are contraindicated and specific regimens are needed 2
- Significant drug-drug interactions exist that cannot be managed 1
Why This Approach Works
The 2020 EASL guidelines specifically created this simplified pathway because:
- Modern pangenotypic DAAs are highly effective across all genotypes
- Genotype testing creates barriers to treatment access
- The risk-benefit strongly favors early treatment initiation in compensated patients
- Lower SVR rates in genotype 3 with cirrhosis can be addressed with effective retreatment strategies if needed 1
Monitoring Considerations
While the guidelines state that SVR testing can be omitted in adherent patients with low reinfection risk 1, practical considerations in real-world practice suggest confirming SVR at 12 weeks post-treatment, especially if:
- Adherence is uncertain
- The patient has risk factors for reinfection
- Insurance or documentation requirements exist
The bottom line: If your patient has no clinical evidence of decompensation, start treatment now with a pangenotypic regimen. Do not delay therapy waiting for imaging or genotype results. The ultrasound can be obtained during or after treatment to assess for hepatocellular carcinoma surveillance needs, and genotype information, while potentially useful for optimization, is not required for effective treatment in this population.